Skin and Connective Tissue Diseases: Clinical Trials

20031 completed, 5186 unknown, 4389 recruiting, 3144 terminated. 9892 Not applicable, 9497 Phase 2, 5578 Phase 1, 4433 Phase 3, 2024 Phase 4.

By phase and status

Phase	Trials	Status
Not applicable	9892	Completed 5144, Unknown 1575, Recruiting 1212, Not yet recruiting 575, Terminated 517, Active not recruiting 462, Withdrawn 299, Enrolling by invitation 82, Suspended 26
Phase 2	9497	Completed 4796, Terminated 1302, Recruiting 1015, Unknown 1015, Active not recruiting 550, Not yet recruiting 380, Withdrawn 379, Enrolling by invitation 31, Suspended 29
Phase 1	5578	Completed 2988, Terminated 713, Recruiting 672, Unknown 444, Active not recruiting 329, Withdrawn 225, Not yet recruiting 157, Suspended 29, Enrolling by invitation 21
Phase 3	4433	Completed 2648, Unknown 441, Recruiting 381, Terminated 360, Active not recruiting 321, Not yet recruiting 137, Withdrawn 106, Enrolling by invitation 28, Suspended 11
Phase 4	2024	Completed 1153, Unknown 329, Terminated 163, Recruiting 162, Not yet recruiting 87, Withdrawn 76, Active not recruiting 43, Enrolling by invitation 11
Early Phase 1	547	Completed 222, Recruiting 84, Unknown 80, Terminated 49, Withdrawn 46, Not yet recruiting 40, Active not recruiting 18, Enrolling by invitation 6, Suspended 2

Follow Skin and Connective Tissue Diseases: new trials by email Literature Review of Skin and Connective Tissue Diseases trials Research Report on Skin and Connective Tissue Diseases

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM - Common Wart	Phase 2	Suspended	G&E Herbal Biotechnology Co., LTD	102	2030-09-01	2023-09-14
Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Site specific standard of care comparison - Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis		Withdrawn	Massachusetts General Hospital		2030-01-01	2026-01-16
Cannabichromene Safety in Rheumatoid Arthritis Cannabichromene - Arthritis, Rheumatoid	Phase 1 / Phase 2	Withdrawn	Crystal Lederhos Smith		2028-07-15	2026-09-23
Application of Multimodal MRI-based Radiomics in Histological Grading and Prognostic Assessment of Breast Cancer DCE-MRI - Breast Cancer, Breast Cancer With Low to Intermediate HER2 Expression		Not yet recruiting	Hao Xu	400	2028-01-01	2026-02-05
An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis	Early Phase 1	Withdrawn	Institute of Hematology & Blood Diseases Hospital, China		2027-12-01	2026-06-10
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP) CB-010 - Systemic Lupus Erythematosus, Lupus	Phase 1	Withdrawn	Caribou Biosciences, Inc.		2027-12-01	2025-09-19
Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer Resistant Potato Starch, Placebo control - Breast Cancer, HER-2 Positive Breast Cancer	Not applicable	Not yet recruiting	University of Vermont Medical Center	12	2027-10-01	2026-02-12
Assessment of the Prevalence of Rheumatic Heart Disease in School Settings in Mayotte and the Acquisition of Ultrasound Sequences Guided by Artificial Intelligence Ultrasound performed bycardiologis for diagnosis of rheumatic heart disease - Rheumatic Heart Diseases, Scabies	Not applicable	Not yet recruiting	Centre Hospitalier Universitaire de la Réunion	900	2027-10-01	2026-10-29
Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis Acetyl Salicylic Acid (ASA), Placebo - Giant Cell Arteritis (GCA), Acute Coronary Syndrome (ACS)	Phase 3	Not yet recruiting	Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal	120	2027-10-01	2026-10-30
A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediated Kidney Diseases CD19-targeted iNKT Cell Injection - IgA Nephropathy (IgAN), Membranous Nephropathy	Early Phase 1	Not yet recruiting	Grit Biotechnology	30	2027-08-01	2026-09-11
Developing and Testing the Efficacy of AI-Chatbot-Based AIAI-Chatbot CalmMindRecoveryJourney delivering BMS-MC therapy - Breast Cancer	Not applicable	Not yet recruiting	National Taiwan University Hospital	68	2027-08-01	2026-08-27
Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERIT Trametinib - HCM, Noonan Syndrome and Other Rasopathy	Phase 3	Not yet recruiting	Carelon Research	25	2027-08-01	2026-09-14
Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma	Phase 1 / Phase 2	Not yet recruiting	Northwestern University	44	2027-07-01	2026-08-03
EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors EmpowerHer Hybrid Program - Breast Cancer, Cancer Survivors	Not applicable	Not yet recruiting	University of Valencia	147	2027-07-01	2026-06-30
Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy - Metastatic Invasive Breast Cancer, Resistant Breast Cancer	Phase 2	Not yet recruiting	University of California, San Diego	150	2027-07-01	2026-07-27
Combination Immunotherapy Targeting Melanoma Antigen-specific CAR T, CTL and DCvac to treat melanoma. - Melanoma	Phase 1 / Phase 2	Not yet recruiting	Shenzhen Geno-Immune Medical Institute	30	2027-06-30	2026-10-30
On the Move: Center and Home-Based Exercise to Enhance Mobility in Diabetic Foot Ulcer Recovery 12-week exercise regimen, 12-week standard of care - Diabetic Foot Ulcer	Not applicable	Not yet recruiting	University of Maryland, Baltimore	60	2027-06-01	2026-10-07
Korea Post Marketing Surveillance (PMS) Study of Talzenna® Talzenna - Breast Neoplasms		Withdrawn	Pfizer		2027-06-01	2026-09-14

Showing 20 of 38063. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (13516)  ·  Arthritis, Rheumatoid (3284)  ·  Melanoma (3200)  ·  Dermatitis, Atopic (1512)  ·  Psoriasis (1464)  ·  Triple Negative Breast Neoplasms (1201)  ·  Lupus Erythematosus, Systemic (1183)  ·  Neoplasms (1086)  ·  Diabetic Foot (1031)  ·  Neoplasm Metastasis (825)  ·  Carcinoma, Non-Small-Cell Lung (816)  ·  Acne Vulgaris (779)  ·  Ovarian Neoplasms (764)  ·  Colorectal Neoplasms (731)  ·  Lung Neoplasms (706)

Broader conditions

Skin Diseases (31312)  ·  Neoplasms by Site (17806)  ·  Neoplasms (17552)  ·  Breast Diseases (14391)  ·  Immune System Diseases (8503)  ·  Connective Tissue Diseases (7803)  ·  Pathological Conditions, Signs and Symptoms (6157)  ·  Musculoskeletal Diseases (5509)  ·  Autoimmune Diseases (5413)  ·  Neoplasms by Histologic Type (4939)  ·  Joint Diseases (4457)  ·  Arthritis (4110)  ·  Rheumatic Diseases (3964)  ·  Pathologic Processes (3780)

Interventions

Cyclophosphamide (873)  ·  Paclitaxel (691)  ·  Trastuzumab (651)  ·  pembrolizumab (544)  ·  Docetaxel (521)  ·  Methotrexate (481)  ·  Capecitabine (458)  ·  Carboplatin (395)  ·  Letrozole (390)  ·  Fulvestrant (348)  ·  Nivolumab (339)  ·  Doxorubicin (333)  ·  Blood Specimen Collection (328)  ·  Standard of Care (303)  ·  Tamoxifen (286)

Sponsors

National Cancer Institute (NCI) (524)  ·  Pfizer (507)  ·  Novartis Pharmaceuticals (494)  ·  Hoffmann-La Roche (453)  ·  M.D. Anderson Cancer Center (352)  ·  Assiut University (337)  ·  Memorial Sloan Kettering Cancer Center (307)  ·  AstraZeneca (289)  ·  GlaxoSmithKline (277)  ·  Bristol-Myers Squibb (269)  ·  Fudan University (264)  ·  Assistance Publique - Hôpitaux de Paris (247)  ·  Mayo Clinic (245)  ·  Amgen (234)  ·  Eli Lilly and Company (218)

Countries

United States (15593)  ·  France (3623)  ·  China (3542)  ·  Germany (2865)  ·  Canada (2782)  ·  Spain (2522)  ·  United Kingdom (2512)  ·  Italy (2247)  ·  Poland (1574)  ·  Australia (1520)  ·  Belgium (1397)  ·  South Korea (1383)  ·  Netherlands (1287)  ·  Turkey (Türkiye) (1225)  ·  Brazil (1059)

Results publications

PMID 33687069, PMID 38979716, PMID 34037241, PMID 32816215, PMID 36931693, PMID 36526796, PMID 34870800, PMID 36600185, PMID 36601090, PMID 33127856, PMID 28143815, PMID 39192350, PMID 25047021, PMID 27338778, PMID 36648215, PMID 33283264, PMID 36326435, PMID 38958913, PMID 37316690, PMID 29244149, PMID 30649524, PMID 36754548, PMID 37453736, PMID 40875187, PMID 29522361, PMID 37906417, PMID 25667295, PMID 26275429, PMID 33263165, PMID 34706874, PMID 37528520, PMID 39588375, PMID 29463520, PMID 32450725, PMID 33826132, PMID 34041702, PMID 34628605, PMID 34741731, PMID 35544084, PMID 36814062, PMID 37945286, PMID 37982966, PMID 40443562, PMID 30739254, PMID 31610021, PMID 31667790, PMID 33874971, PMID 34921355, PMID 35305260, PMID 36205910

NIH funding

2023 (292), 2016 (192), 2018 (186), 2019 (171), 2015 (159), 2014 (151), 2025 (150), 2017 (144), 2009 (102), 2008 (96), P30CA033572 (59), 2005 (57), P30CA015083 (49), P30CA015704 (41), P30CA016672 (38)